BIRMINGHAM, Ala. – October 21, 2015 – Southern Research has received an award from the Cystic Fibrosis Foundation’s nonprofit drug discovery and development affiliate, Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The funding will support research focused on the development of novel drugs for cystic fibrosis (CF) patients with rare genetic mutations, furthering the ultimate goal of treating all people with CF. The milestone-based research phase is for $7.5 million over five years and can be increased to $9 million.

Cystic fibrosis is a life-threatening, genetic disease that affects approximately 30,000 people in the U.S., with almost 1,000 new cases each year, and nearly 70,000 people worldwide. In the U.S., CF is the second most common inherited disease. More than 10 million Americans unknowingly carry the CF gene and there are more than 1,800 mutations of the gene.

Southern Research will be joined in this effort by the University of Alabama at Birmingham (UAB). Southern Research’s High Throughput Screening Center, UAB, and CFFT have been working together for several years investigating the repurposing of known drugs for the treatment of CF.

In addition, through the Alabama Drug Discovery Alliance (ADDA), Southern Research and UAB established a program to look for potential new treatments for several rare genetic diseases such as Hurler’s syndrome, with mutations similar to those found in some CF patients. Initial funding through the ADDA provided the groundwork for this drug discovery project, which originated with UAB’s David Bedwell, Ph.D., and Steven M. Rowe, M.D., working with Southern Research’s HTS group, headed by Bob Bostwick, Ph.D.

“We are excited about the opportunity to expand our relationship with CFFT on the discovery of new treatments for cystic fibrosis,” said Mark J. Suto, Ph.D., vice president of Drug Discovery at Southern Research. “This project highlights the strengths and capabilities of the ADDA, which combines UAB’s basic and clinical research with the drug discovery and development expertise of Southern Research.”

“We are extremely pleased to be working with CFFT and Southern Research in this effort to find therapies for cystic fibrosis patients with a nonsense mutation,” said Steven Rowe, M.D., professor of Medicine at UAB and director of the UAB Gregory Fleming James Cystic Fibrosis Research Center. “The groundbreaking studies of nonsense mutations for this project were done by Dr. David Bedwell, Professor of Microbiology, Genetics and Cell Biology, UAB. With this award, we are uniquely positioned to build on those successes. Our understanding of the genetic causes of cystic fibrosis continues to grow, and we expect meaningful discoveries will result from this work.”

“This is a great achievement for Southern Research and a further testament to the value of the Alabama Drug Discovery Alliance partnership with UAB,” said Southern Research President and CEO, Art Tipton, Ph.D. “We appreciate the confidence that CFFT has placed in our team to identify treatments and therapies that could make a real difference.”

About Southern Research

Southern Research is a not-for-profit 501(c)(3) organization with nearly 500 scientists and engineers working across four divisions: drug discovery, drug development, engineering, and energy and environment.

• We’re developing 18 drugs to combat various forms of cancer, ALS, Alzheimer’s, diabetes, kidney disease, and Parkinson’s, among others.
• We’ve developed seven FDA-approved cancer drugs.
• We’re developing new medical devices.
• We’re helping to launch manned missions to Mars.
• We’re making the air and water cleaner here on Earth.

We work on behalf of the National Cancer Institute, National Institutes of Health, the U.S. Department of Defense, the U.S. Department of Energy, NASA, major aerospace firms, utility companies, and other private and government organizations as we solve the world’s hardest problems. Founded in 1941, Southern Research is headquartered in Birmingham with additional laboratories and offices in Wilsonville and Huntsville, Alabama, Frederick, Maryland, Durham, North Carolina, Cartersville, Georgia, and Houston.

BIRMINGHAM, Ala. – Sept. 8, 2015 – Researchers at Southern Research and the University of Alabama at Birmingham are part of a multisite consortium sharing a new five-year, $3.8 million grant from the National Institute of Neurological Disorders and Stroke CounterACT program, part of the National Institutes of Health, to learn more about organophosphate exposure to the central nervous system.

Organophosphates are chemicals that have been used for decades as pesticides but are also major components of chemical nerve agents that represent a continued threat to military personnel and citizens from terrorist groups and rogue nations. The grant will be used to support research that investigates new chemical and imaging technologies to understand how poisonous organophosphates enter the brain and how antidotes and therapeutics can be used to reduce neurotoxic effects to organophosphate exposures.

The multi-principal investigator team includes John Gerdes, Ph.D., senior research fellow and director of neurobiology, Southern Research, Kurt Zinn, DVM, Ph.D., professor and vice chair of Translational Research in the UAB Department of Radiology, Henry VanBrocklin, Ph.D., professor of radiology at the University of California, San Francisco, and Charles Thompson, Ph.D., professor of biomedical & pharmaceutical sciences at the University of Montana.

Central to the award is the utilization of positron emission tomography ¬– or PET imaging – to evaluate organophosphate exposures and the efficacy of the therapeutics in hopes of developing highly useful clinical tools and therapeutic inventions.

PET imaging has been used widely in cancer diagnosis and to determine the progress of certain neurodegenerative diseases such as Parkinson’s and Alzheimer’s. This research is the first use of PET imaging to study toxic organophosphates. The researchers are hopeful that this PET imaging investigation will unveil important characteristics about brain susceptibility to toxic agents and guide drug development that halts or reverses the toxic effects following organophosphate exposures.

About Southern Research
Southern Research is a not-for-profit 501(c)(3) organization with nearly 500 scientists and engineers working across four divisions: drug discovery, drug development, engineering, and energy and environment.

• We’re developing 18 drugs to combat various forms of cancer, ALS, Alzheimer’s, diabetes, kidney disease, and Parkinson’s, among others.
• We’ve developed seven FDA-approved cancer drugs.
• We’re developing new medical devices.
• We’re helping to launch manned missions to Mars.
• We’re making the air and water cleaner here on Earth.

We work on behalf of the National Cancer Institute, National Institutes of Health, the U.S. Department of Defense, the U.S. Department of Energy, NASA, major aerospace firms, utility companies, and other private and government organizations as we solve the world’s hardest problems. Founded in 1941, Southern Research is headquartered in Birmingham with additional laboratories and offices in Wilsonville and Huntsville, Frederick, Maryland, Durham, North Carolina, Cartersville, Georgia, and Houston. Learn more at southernresearch.org.

About UAB
Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is an internationally renowned research university and academic medical center, as well as Alabama’s largest employer, with some 23,000 employees, and has an annual economic impact exceeding $5 billion on the state. The five pillars of UAB’s mission include education, research, patient care, community service and economic development. UAB is a two-time recipient of the prestigious Center for Translational Science Award. Learn more at www.uab.edu. UAB: Knowledge that will change your world.

Media Contacts:
Southern Research: Rossi Morris
205-581-2266 or rmorris@southernresearch.org
UAB: Bob Shepard
205-934-8934 or bshep@uab.edu

Since its founding in 1941, Southern Research has been actively participating in training the next generation of scientists. Various faculty members in Southern Research’s drug discovery division hold academic appointments in departments at the University of Alabama at Birmingham (UAB) School of Medicine. They also serve as training members of the UAB Graduate School.

Over the years, numerous graduate students have completed their doctoral thesis research in Southern Research labs. In addition, postdoctoral training is a major training mission in the drug discovery division. Many Southern Research postdoctoral trainees have advanced their scientific careers to become independent researchers in both academia and industry.

In October 2013, Southern Research, in collaboration with the American Immigration Council, initiated a J-1 Visa training program for international trainees. The program allows international interns and trainees to work in Southern Research labs for up to 18 months of training on biomedical research.

“Training international scholars further fulfils Southern Research’s mission of education and creates potential international collaborations for research in precision medicine in the future,” said Bo Xu, M.D., Ph.D., Southern Research’s cancer research department chairman.

Chunling Jiang, M.D., of Jiangxi Provincial Cancer Hospital in China, was the first to complete her one-year training in the oncology groups in fall 2014. Dr. Jiang is a seasoned radiation oncologist interested in developing novel approaches to helping cancer patients receiving radiotherapy. With bench-to-bedside training, she gained the knowledge and skills to conduct translational oncology research. Shang Cai, M.D. and Ph.D. candidate, from Soochow University in China is currently conducting training in the oncology groups at Southern Research.

For additional information about the program, contact Dr. Bo Xu, in the Southern Research Drug Discovery Oncology department.

BIRMINGHAM, Ala. – August 12, 2015 – Southern Research won a grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health to develop opioid drugs for the treatment of chronic pain. These candidate compounds are being developed to have fewer adverse effects than currently marketed opioid pain-relief medications, such as morphine. The award is for $4.5 million for up to five years, under award number R01DA038635.

The funds will be applied to the discovery and development of improved therapeutic agents for the treatment of pain. Research will involve the design and synthesis of new compounds and their evaluation in vitro and in vivo to identify candidate compounds with potential for further development.

Chronic pain affects an estimated 100 million Americans. The economic burden of chronic pain in the U.S. was recently estimated at approximately $600 billion per year – greater than the combined annual cost of cancer, heart disease, and diabetes.

Opioids are currently the most useful treatments available for moderate to severe acute and chronic pain, but their therapeutic use is limited due to their tendency to produce adverse side effects, including drowsiness, mental confusion, nausea, constipation, and respiratory depression. With longer term use, abuse is a factor including physical dependence, and addiction. Opioid medications include hydrocodone, oxycodone, morphine, codeine, and related drugs.

“There is a crucial, medical need for novel painkillers that are as effective as morphine, without the significant side effects,” said Subramaniam Ananthan, Ph.D., principal investigator and principal research scientist in drug discovery at Southern Research. “We recently discovered novel opioid compounds possessing analgesic activity with diminished propensity to induce tolerance. The goal of this grant will be to further the development of a potential compound with improved bioavailability for clinical development.”

The research will be led by Ananthan and performed by a team of scientists at Southern Research and the University of New England, with expertise in medicinal chemistry, molecular modeling, in vitro and in vivo opioid pharmacology, and drug metabolism/pharmacokinetics (DMPK).

“From our previous research, we have a better understanding of the neurobiology of opioid systems, pain, and addiction, and the scientists at Southern Research were able to synthesize lead molecules that interact with the opioid receptors in a novel way, providing pain relief, while having greatly reduced side effects,” said Edward Bilsky, Ph.D., University of New England vice president for research and scholarship and professor of pharmacology. “This new grant award from the National Institutes of Health is timely and critical for advancing the project towards the goal of having a clinical drug candidate for treatment of acute and chronic pain and will enable us to further refine these molecules and validate them for testing in humans.”

Bilsky has collaborated with Ananthan for over 20 years in the fields of opioid pharmacology, pain, and drug addiction.

“Dr. Ananthan is a highly-knowledgeable medicinal chemist with extensive experience in drug discovery and an exceptional publication record,” said Mark J. Suto, Ph.D., vice president of drug discovery at Southern Research. “The team of researchers is well qualified to handle this project, and they have a long-standing record of successful collaboration. I look forward to their progress.”

About Southern Research
Southern Research is a not-for-profit 501(c)(3) organization with nearly 500 scientists and engineers working across four divisions: drug discovery, drug development, engineering, and energy and environment.

• We’re developing 18 drugs to combat various forms of cancer, ALS, Alzheimer’s, diabetes, kidney disease, and Parkinson’s, among others.
• We’ve developed seven FDA-approved cancer drugs.
• We’re developing new medical devices.
• We’re helping to launch manned missions to Mars.
• We’re making the air and water cleaner here on Earth.

We work on behalf of the National Cancer Institute, National Institutes of Health, the U.S. Department of Defense, the U.S. Department of Energy, NASA, major aerospace firms, utility companies, and other private and government organizations as we solve the world’s hardest problems.

Southern Research, founded in 1941, is headquartered in Birmingham with additional laboratories and offices in Wilsonville and Huntsville, Frederick, Maryland, Durham, North Carolina, Cartersville, Georgia, and Houston.